AZRX - AzurRx BioPharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.8301
-0.0665 (-7.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.8966
Open0.8800
Bid0.0000 x 800
Ask0.0000 x 3100
Day's Range0.7801 - 0.8800
52 Week Range0.3710 - 1.9380
Volume282,148
Avg. Volume298,172
Market Cap23.411M
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AZRX: Next Up: OPTION 2
    Zacks Small Cap Research

    AZRX: Next Up: OPTION 2

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT On May 15th, 2020, AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its first quarter 2020 10-Q with the SEC for the three month period ending March 31, 2020. Highlights year to date include the appointment of a new CFO and board member, receipt of ~$3.5 million in French tax credits, confirmation of manufacturing and distribution

  • Here is What Hedge Funds Think About AzurRx BioPharma, Inc. (AZRX)
    Insider Monkey

    Here is What Hedge Funds Think About AzurRx BioPharma, Inc. (AZRX)

    In this article you are going to find out whether hedge funds think AzurRx BioPharma, Inc. (NASDAQ:AZRX) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

  • What Kind Of Share Price Volatility Should You Expect For AzurRx BioPharma, Inc. (NASDAQ:AZRX)?
    Simply Wall St.

    What Kind Of Share Price Volatility Should You Expect For AzurRx BioPharma, Inc. (NASDAQ:AZRX)?

    Anyone researching AzurRx BioPharma, Inc. (NASDAQ:AZRX) might want to consider the historical volatility of the share...

  • AZRX: EPI Treatment in the News
    Zacks Small Cap Research

    AZRX: EPI Treatment in the News

    By John Vandermosten, CFA NASDAQ:AZRX Infectious Disease With the concerns related to the emergence of the novel coronavirus in the news on a daily basis, attention to animal-sourced product used in medicines has also come in to focus. Fears are also rising related to the transmission of animal viruses passing to humans, similar to what happened in the Avian Flu outbreaks from 2013 to 2017 in

  • Benzinga

    The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO

    Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech stocks closed 2019 with gains, although they underperformed ...

  • AZRX: 3Q:19 Review
    Zacks Small Cap Research

    AZRX: 3Q:19 Review

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its 2019 third quarter 10-Q with the SEC for the three month period ending September 30, 2019. Highlights for the reporting period and to date include the announcement and first dosing in a new combination trial for patients with severe EPI, the readout from the OPTION trial, the

  • AZRX: OPTION Trial Readout
    Zacks Small Cap Research

    AZRX: OPTION Trial Readout

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) announced Phase II OPTION trial results for MS1819 in cystic fibrosis (CF) patients. Data provided was sparse, but the summary highlighted the positive safety profile for MS1819 and the utility of the drug in comparison with porcine enzyme replacement

  • Benzinga

    The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The ...

  • Benzinga

    AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency

    AzurRx is working on developing non-systemic, recombinant therapies for gastrointestinal diseases. The company said the results of the Phase 2 OPTION trial that is evaluating its MS1819 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis showed that the primary efficacy endpoint of coefficient of fat absorption, or CFA, was comparable to that in a previous Phase 2 study in patients with chronic pancreatitis. Despite the study not being powered for statistical significance, the data showed meaningful efficacy results, with about 50% of patients showing CFAs high enough to reach non-inferiority with porcine enzyme replacement therapies, or PERT, AzurRx said.

  • What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?

    A look at the shareholders of AzurRx BioPharma, Inc. (NASDAQ:AZRX) can tell us which group is most powerful. Large...

  • Zacks Small Cap Research

    AZRX: OPTION & Combo Trial Underway

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its 2019 second quarter 10-Q with the SEC for the three month period ending June 30, ...

  • Zacks Small Cap Research

    AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI

    The effort will examine combination use of MS1819-SD and pancreatic enzyme replacement therapy (PERT) for cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI). This is a subset of CF patients that are suffer from malnutrition and fail to absorb sufficient fat despite taking the maximum dose of PERT therapy. The new study will be conducted at six sites in Hungary with an enrollment target of 28.